LLY

879.51

-2.09%↓

JNJ

239.74

+0.04%↑

ABBV

209.86

-0.59%↓

NVS

148.06

-1.14%↓

MRK

119.75

+0.73%↑

LLY

879.51

-2.09%↓

JNJ

239.74

+0.04%↑

ABBV

209.86

-0.59%↓

NVS

148.06

-1.14%↓

MRK

119.75

+0.73%↑

LLY

879.51

-2.09%↓

JNJ

239.74

+0.04%↑

ABBV

209.86

-0.59%↓

NVS

148.06

-1.14%↓

MRK

119.75

+0.73%↑

LLY

879.51

-2.09%↓

JNJ

239.74

+0.04%↑

ABBV

209.86

-0.59%↓

NVS

148.06

-1.14%↓

MRK

119.75

+0.73%↑

LLY

879.51

-2.09%↓

JNJ

239.74

+0.04%↑

ABBV

209.86

-0.59%↓

NVS

148.06

-1.14%↓

MRK

119.75

+0.73%↑

Search

CorMedix Inc

Abierto

SectorSanidad

6.85 1.93

Resumen

Variación precio

24h

Actual

Mínimo

6.61

Máximo

6.98

Métricas clave

By Trading Economics

Ingresos

-95M

14M

Ventas

24M

129M

P/B

Media del Sector

3.147

57.05

BPA

0.16

Margen de beneficios

10.901

Empleados

191

EBITDA

9.2M

66M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+100.45% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-61M

508M

Apertura anterior

4.92

Cierre anterior

6.85

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

333 / 349 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

CorMedix Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 mar 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26 mar 2026, 23:36 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26 mar 2026, 23:35 UTC

Adquisiciones, fusiones, absorciones

Pernod Ricard: Confirms Discussions With Brown-Forman

26 mar 2026, 23:29 UTC

Ganancias

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26 mar 2026, 23:28 UTC

Ganancias

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26 mar 2026, 23:28 UTC

Ganancias

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26 mar 2026, 23:28 UTC

Ganancias

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26 mar 2026, 23:27 UTC

Ganancias

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26 mar 2026, 23:27 UTC

Ganancias

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26 mar 2026, 23:08 UTC

Charlas de Mercado

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26 mar 2026, 23:04 UTC

Adquisiciones, fusiones, absorciones

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26 mar 2026, 23:04 UTC

Adquisiciones, fusiones, absorciones

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26 mar 2026, 23:04 UTC

Adquisiciones, fusiones, absorciones

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26 mar 2026, 23:04 UTC

Adquisiciones, fusiones, absorciones

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26 mar 2026, 23:04 UTC

Adquisiciones, fusiones, absorciones

Pernod in Deal Talks With Brown-Forman -- WSJ

26 mar 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26 mar 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26 mar 2026, 22:26 UTC

Ganancias

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26 mar 2026, 22:26 UTC

Ganancias

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26 mar 2026, 22:26 UTC

Ganancias

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26 mar 2026, 22:08 UTC

Ganancias

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26 mar 2026, 22:08 UTC

Ganancias

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26 mar 2026, 22:08 UTC

Ganancias

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26 mar 2026, 22:07 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Global Energy Roundup: Market Talk

26 mar 2026, 22:07 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26 mar 2026, 22:00 UTC

Ganancias

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26 mar 2026, 22:00 UTC

Ganancias

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26 mar 2026, 22:00 UTC

Ganancias

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26 mar 2026, 21:39 UTC

Adquisiciones, fusiones, absorciones

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26 mar 2026, 21:38 UTC

Adquisiciones, fusiones, absorciones

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Comparación entre iguales

Cambio de precio

CorMedix Inc previsión

Precio Objetivo

By TipRanks

100.45% repunte

Estimación a 12 Meses

Media 13.25 USD  100.45%

Máximo 14 USD

Mínimo 13 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CorMedix Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

9.2 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

333 / 349 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
help-icon Live chat